Cellebrite DI (NASDAQ:CLBT - Get Free Report) had its price target increased by analysts at JPMorgan Chase & Co. from $21.00 to $22.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price points to a potential upside of 17.08% from the company's previous close.
A number of other brokerages have also issued reports on CLBT. Lake Street Capital upped their target price on shares of Cellebrite DI from $13.50 to $17.00 and gave the stock a "buy" rating in a research report on Friday, August 16th. Needham & Company LLC increased their price objective on Cellebrite DI from $17.00 to $21.00 and gave the company a "buy" rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft lifted their target price on Cellebrite DI from $15.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Bank of America upped their price target on Cellebrite DI from $13.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Finally, Craig Hallum lifted their price objective on Cellebrite DI from $20.00 to $23.00 and gave the stock a "buy" rating in a research report on Wednesday, September 25th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $20.29.
Check Out Our Latest Stock Analysis on Cellebrite DI
Cellebrite DI Stock Performance
Shares of CLBT stock traded down $0.30 during mid-day trading on Thursday, reaching $18.79. The company's stock had a trading volume of 1,210,618 shares, compared to its average volume of 1,144,243. The firm's 50-day moving average is $17.59 and its two-hundred day moving average is $14.23. The company has a market cap of $3.87 billion, a P/E ratio of -12.12, a PEG ratio of 2.55 and a beta of 1.50. Cellebrite DI has a 1-year low of $7.22 and a 1-year high of $21.00.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, August 15th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.08 by $0.02. Cellebrite DI had a positive return on equity of 5,902.06% and a negative net margin of 28.51%. The company had revenue of $95.70 million for the quarter, compared to analysts' expectations of $91.94 million. During the same quarter in the prior year, the business earned $0.05 earnings per share. The business's revenue for the quarter was up 24.8% on a year-over-year basis. Sell-side analysts anticipate that Cellebrite DI will post 0.31 EPS for the current year.
Hedge Funds Weigh In On Cellebrite DI
Several institutional investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. increased its position in shares of Cellebrite DI by 59.6% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company's stock valued at $33,000 after buying an additional 1,017 shares in the last quarter. Pathway Financial Advisers LLC grew its stake in Cellebrite DI by 1,583.8% in the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company's stock valued at $74,000 after acquiring an additional 4,118 shares during the period. Public Employees Retirement Association of Colorado bought a new stake in shares of Cellebrite DI in the second quarter worth about $71,000. nVerses Capital LLC bought a new position in shares of Cellebrite DI during the 2nd quarter valued at about $103,000. Finally, Venturi Wealth Management LLC lifted its holdings in shares of Cellebrite DI by 28.6% during the 3rd quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company's stock valued at $152,000 after purchasing an additional 2,000 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.
Cellebrite DI Company Profile
(
Get Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
